Tanios S. Bekaii-Saab, MD, FACP, details data from the ESOPEC trial in early-stage gastroesophageal cancers, and findings from Checkmate-9DW in HCC. Tanios Bekaii-Saab, MD @mayoclinic ASCO #ASCO24 #oncology onclive.com/view/complexit…

Tanios S. Bekaii-Saab, MD, highlights data from the phase 1/2 ARC-9 study which showed promising overall survival data in patients with colorectal cancer. Tanios Bekaii-Saab, MD Mayo Clinic Comprehensive Cancer Center #crcsm #oncology onclive.com/view/longest-o…

Findings from the phase 3 ESOPEC trial have demonstrated that radiation therapy may not be necessary for most patients with early-stage gastroesophageal cancers. Tanios Bekaii-Saab, MD @mayoclinic ASCO #ASCO24 #oncology onclive.com/view/complexit…

REGISTER: OncLive.com's State of the Science Summit: #BreastCancer, w/ Mayo Clinic medical oncologist Dr. Lida Mina: bit.ly/4dzLubv Topics include: ➡ HER2+ BC management ➡ Early-stage ER+ BC ➡ Metastatic ER+ BC ➡ #TNBC advances ➡ Novel & promising Targets ➡ Live Q&A

.Mayo Clinic medical oncologist and researcher Dr. Tanios Bekaii-Saab @GICancerDoc discusses final results from the MOUNTAINEER trial in HER2+ metastatic #ColorectalCancer. Via OncLive.com bit.ly/3Avv6un

Join us in Miami, FL, US for #ISGIO! We’ll talk about #GI cancers #hepatobiliary cancers with clinical cases, lectures, and discussions! Tanios Bekaii-Saab, MD Eileen M O’Reilly Humanitas University Humanitas Milano PER

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer. Tanios Bekaii-Saab, MD Mayo Clinic #crcsm onclive.com/view/analyzing…

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

Congratulations to our OncoAlert 🚨faculty and amazing friend Toni Choueiri, MD and team: LITESPARK-005 out on NEJM

Join world-renowned #GICancer experts in Hollywood, FL for cutting-edge insights, lively discussions, and networking opportunities. Register now, and don’t forget your swimsuit!😎🌴bit.ly/44Cwoii #ISGIO #CME Tanios Bekaii-Saab, MD Mayo Clinic Eileen M O’Reilly Memorial Sloan Kettering Cancer Center

Join us in Hollywood, FL for PER’s #ISGIO! Learn about the latest advances in the field of #GIcancer research, and critical issues for the care of persons with GI cancer. Register now:bit.ly/4aR1Hrl #gotoPER #ISGIO Tanios Bekaii-Saab, MD Eileen M O’Reilly Humanitas Milano Humanitas University

Explore the impacts of age, ethnicity, socioeconomic status, and healthcare access for patient's with CRC, with hosts the Oncology Brothers, and experts @gicancerdoc and Deneen Richmond Learn to delve deeper for your patients in this #MedEd podcast Listen here: ow.ly/YLsp50TetPH

My second book “THE CANCER JOURNEY” launches 9/24/24 & is available to pre-order a.co/d/f0mwZCZ I leverage storytelling to explain & simplify everything related to cancer from A-Z; written in an easy to read & understand language so it reaches everyone. Check it out.

🚨Such a delight to host a JAMA Oncology PODCAST with the amazing Eileen M O’Reilly Memorial Sloan Kettering Cancer Center - we talk about how an #AI based classifier reclassified approximately 20% of cases with pancreatic cancer. 👉🏼#immunotherapy for patients with Lynch syndrome or somatic MSI-H PanCAN

🌴Just one month until the #ISGIO conference in Hollywood, FL! Reserve your spot now to connect with world-renowned experts in #GICancer care and explore the latest advancements: bit.ly/3UAJEiR #gotoPER #CME Tanios Bekaii-Saab, MD Mayo Clinic Eileen M O’Reilly Memorial Sloan Kettering Cancer Center

mFOLFIRINOX with conventional CRT did not improve R0 nor OS compared to mFOLFIRINOX without preoperative CRT in patients with BRPC. ESMO - Eur. Oncology

#colorectalcancer #gicancer #cholangiocarcinoma #gastriccancer

Save the date for #ESMO25 in Berlin! Honored to be the Scientific co-Chair with Myriam Chalabi —Stay tuned for the ESMO - Eur. Oncology program!

Interesting results 🧐from the #TOPGEAR study: preoperative chemoradiotherapy in resectable #GastricCancer. 📈Pathological complete response was 17% with chemoradiotherapy compared to 8% with chemotherapy. Median overall survival was 46 months with chemoradiotherapy and 49

Less than a month away - come to Hollywood, FL this fall for PER’s ISGIO to review advances in GI cancers! 👇looking forward to participate with this faculty of #GIcancer experts! Register today for FREE using my last name as a discount code - GILL - 🔗 bit.ly/4aR1Hrl